Eve Review
Best for: **Women** seeking a women's-health-focused GLP-1 telehealth platform with dual access to either affordable compounded GLP-1 ($195/mo) OR brand-name FDA-approved Ozempic / Wegovy / Mounjaro ($1,399-$1,699/mo cash-pay), with LegitScript verification and a satisfaction guarantee. Strong fit for buyers who want a single platform supporting both ends of the compounded-vs-brand-name choice without switching providers.
Eve (tryeve.co) is a women's-health-focused GLP-1 telehealth platform — distinctive positioning vs the male-default DTC market. Tagline: 'Empowering Women's Health.' DUAL-MODALITY OFFERING (rare in the WLR directory — only Brightmeds + Eve offer both): compounded semaglutide $195/month (injection + oral sublingual forms), compounded tirzepatide $195/month, PLUS brand-name FDA-approved Ozempic® $1,399/month, Mounjaro® $1,399/month, Wegovy® $1,699/month. Payment model: 'You pay $0 unless approved by a licensed physician.' Free shipping on orders above $50. Satisfaction guarantee: 'We're confident you'll love it—or your money back.' Subscription cancelable anytime. LegitScript Certified with verifiable ID 42862417. Verbatim FDA disclaimer published: 'The FDA does not review or approve any compounded medications for safety or effectiveness.' Multi-state coverage implied (verbatim: 'If you relocate to a state we currently serve, your treatment can continue seamlessly') but explicit states list NOT disclosed. Pharmacy partner, 503A vs 503B designation, named medical director, corporate legal entity, and governing law are NOT publicly disclosed. Live-verified 2026-05-19.
Medium confidence · Last verified 2026-05-19 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Eve is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Eve prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Standard tier — Compounded GLP-1 | compounded | $195 |
| Sublingual / oral | compounded-oral | $195 |
| Standard tier — Compounded GLP-1 | compounded | $195 |
| Brand-name Ozempic® | brand | $1399 |
| Brand-name Wegovy® | brand | $1699 |
| Brand-name Mounjaro® | brand | $1399 |
✓ Pros
- •**Women's-health-focused brand positioning** is genuinely differentiated — most DTC GLP-1 competitors default to gender-neutral or male framing; Eve fills a real market gap
- •**Dual modality access** (compounded + brand-name FDA-approved) — patients who prefer Wegovy/Ozempic/Mounjaro can access them on the same platform as compounded options; rare in the DTC directory (Brightmeds is the only other one)
- •LegitScript Certified with publicly verifiable ID (42862417) — strong trust signal beyond just the badge
- •Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- •Oral SUBLINGUAL semaglutide offered alongside injectable — auto-classifies into /best/oral-glp1-providers via description regex
- •'$0 unless approved' payment model reduces sign-up risk significantly
- •Satisfaction guarantee / money-back available
- •Free shipping above $50 threshold (most orders qualify)
✗ Cons
- •Full states-served list NOT disclosed publicly — only implied via relocation-continuity framing
- •Specific 503A pharmacy partner NOT named
- •503A vs 503B compounding designation NOT specified
- •LegitScript ID published (42862417) but not embedded in text — only in the seal image
- •Named medical director / clinical leadership NOT disclosed
- •Corporate legal entity (LLC/Inc/PC) NOT disclosed
- •Governing law / arbitration venue NOT publicly stated
- •Brand-name pricing ($1,399-$1,699/mo) is roughly retail cash-pay — does NOT appear to include savings card or insurance pathways; patients with insurance should price-compare elsewhere first
- •Subscription cancellation allowed but refund policy text not detailed publicly
Ready to start with Eve?
Starting at $195/month. See current pricing and start your free consultation.
Sources & methodology
Our Eve review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Eve
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Eve?
Starting at $195/month. See current pricing and start your free consultation.